Targeting the Tumor Microenvironment in Blood Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 205

Special Issue Editors


E-Mail Website
Guest Editor
Section of Pharmacology, Department of Precision and Regenerative Medicine and Jonian Area, School of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy
Interests: pharmacology; ion channels; cancer; multiple myeloma; pancreatic cancer; tumor microenvironment; non-dystrophic myotonias; drug repurposing; precision medicine
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Section of Pharmacology, Department of Precision and Regenerative Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy
Interests: pharmacology; ion channels; acquired channelopathies (cancer); pancreatic cancer; rare diseases; genetic channelopathies; non-dystrophic myotonias; drug repurposing; precision medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Hematological malignancies represent the fifth most common cancer worldwide. Although the recent advances in pharmacotherapy have significantly improved patient survival, few therapeutic options remain for some hematological diseases. Hence, a deeper understanding of blood cancer pathogenesis will provide the basis for the design of novel drugs and the improvement of clinical practice.   

To date, it is widely established that the tumor microenvironment plays a pivotal role in the development of blood cancers, sustaining tumor progression, angiogenesis, immune suppression, and drug resistance. Increasing studies are currently investigating novel “players” (e.g. cytokines, deregulated pathways, immune system, epigenetics, miRNAs, extracellular vesicles, and, metabolites) involved in the mutual crosstalk that remodel the tumor milieu, creating a pro-survival niche. 

Therefore, targeting the tumor microenvironment represents an attractive strategy to enhance the efficacy of tumor-targeting drugs and to prevent pharmacological escape, improving patients’ outcome. 

This Special Issue will focus on the novel preclinical and clinical therapeutic strategies able to target the tumor microenvironment in order to overcome its protective effect in hematological malignancies. 

For this Special Issue, authors are encouraged to submit original research, systematic reviews, and review articles.

Dr. Ilaria Saltarella
Dr. Concetta Altamura
Dr. Paola Poma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hematological cancers
  • tumor microenvironment
  • multiple myeloma
  • leukemia
  • lymphoma
  • myelodysplastic syndromes
  • therapeutic targets
  • drug repurposing
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop